To orderthis 540+ page report, please visit this - https://www.rootsanalysis.com/reports/view_document/large-volume-wearable-injectors/238.html
KeyInclusions
§ An overview ofcurrent market landscape of the large volume wearable injectors available fordelivery of insulin and non-insulin drugs, providing information on status ofdevelopment and device specifications, such as type of device (patch pump /injector and infusion pump / injector), type of dose administered (basal, bolusand others), route of administration (subcutaneous and others), mode ofinjection (needle, needle / cannula and needle / catheter), storage capacity ofthe device, actuation mechanism (electromechanical, rotary pump, cell /expanded battery, pressurized gas, osmotic pressure and others), usability(disposable and reusable), availability of prefilled drug reservoir andavailability of device connectivity. The report also features additionalinformation on availability of prefilled insulin cartridges, availability ofcontinuous glucose monitoring / blood glucose monitoring (CGM / BGM) systems,availability of Automated Insulin Delivery feature and type of remote controlfeatures (control within device / personal diabetes manager (PDM) / smartphone)in the insulin delivery devices.
§ A detailedcompetitiveness analysis of large volume wearable injectors based on variousrelevant parameters, such as supplier power (based on the experience /expertise of the developer) and product specifications (type of device, type ofdose, storage capacity of the device, usability, route of administration,connectivity and availability of a continuous glucose monitoring / bloodglucose monitoring (CGM / BGM) systems (in case of insulin devices).
§ Elaborate profiles ofthe prominent companies that develop large volume wearable injectors. Eachcompany profile features a brief overview of the company, its financialinformation (if available), information on its product portfolio, recentdevelopments and an informed future outlook. Additionally, the report includestabulated profiles of wearable drug device combination products.
§ An analysis of thepartnerships that have been inked by the stakeholders in this domain, duringthe period between 2015 and 2020, covering acquisitions, product developmentagreements, product integration agreements, technology integration agreements,distribution and supply agreements, commercialization agreements, clinical trialagreements, licensing agreements, manufacturing agreements, service agreements, and other relevant typesof deals.
§ A detailed analysison acquisition targets, taking into consideration the historical trend of theactivity of the companies that have acquired other firms since 2000, andoffering a means for other industry stakeholders to identify potentialacquisition targets.
§ An in-depth analysisof the various patents that have been submitted / filed related to large volumewearable injectors over the last three decades. It also highlights the keyparameters associated with the patents, including information on patent type,issuing authority / patent offices involved, Cooperative Patent Classification(CPC) symbols, emerging areas (in terms of number of patents filed / granted),company type and leading industry, non-industry and individual patent assignees(in terms of size of intellectual property portfolio).
§ A list of marketeddrugs / therapies and pipeline candidates that are likely to be developed incombination with large volume wearable injectors in the near future, identifiedon the basis of an in-depth analysis of potential candidates, taking intoconsideration multiple parameters, such as stage of development, dosage, doseconcentration, route of administration, type of dose and drug sales (in case ofmarketed drugs).
§ A social mediaanalysis depicting prevalent and emerging trends, and the popularity of largevolume wearable injectors, as observed on the social media platform, Twitter.The analysis was based on tweets posted on the platform in the last few years.
§ A detailed analysisof completed, ongoing and planned clinical trials of various large volumewearable injector products based on the various relevant parameters, such astrial registration year, current trial phase, trial status, study design, studyfocus, targeted therapeutic area and clinical outcomes.
§ A case study on therole of contract manufacturing organizations in the overall manufacturingprocess / supply chain of wearable injectors. It includes information on theservices provided by contract service providers for manufacturing of variousdevice components (primary containers), infusion sets, adhesives, closures andinjection moldings.
§ An elaboratediscussion on the various guidelines established by major regulatory bodies formedical device approval across North America (the US, Canada and Mexico),Europe (the UK, France, Germany, Italy, Spain and rest of Europe), Asia-Pacificand rest of the world (Australia, Brazil, China, India, Israel, Japan, NewZealand, Singapore, South Africa, South Korea, Taiwan, and Thailand). Thereport also features an insightful multi-dimensional, heat map analysis,featuring a comparison of the contemporary regulatory and reimbursementscenarios in key geographies across the globe.
§ Informed estimates of the existingmarket size and the future opportunity for large volume wearable injectors,over the next decade. Based on parameters, such as the number of commercializeddevices, number of devices under development, price of the device and theannual adoption rate, we have provided an estimate on the likely evolution ofthe large volume wearable injectors market, for the delivery of both insulinand non-insulin drugs, over the period 2020-2030.
The report features the likely distribution of thecurrent and forecasted opportunity across important market segments, mentionedbelow:
§ Typeof Device
- Patch Pump / Injectors
- Infusion Pump / Injectors
§ ProductUsability
- Disposable
- Re-usable
§ TherapeuticArea (for non-insulin drugs)
- Neurological Disorders
- Cardiovascular Disorders
- Oncological Disorders
- Infectious Disorders
§ Key geographical regions
- North America
- Europe
- Asia Pacific
Thereport features inputs from eminent industry stakeholders, according to whom, largevolume injectors are generally preferred for the delivery of biologics, whichcannot be easily administered orally. The report includes detailed transcriptsof discussions held with the following experts:
§ Mark Banister (CEO, Medipacs)
§ Michael Hooven (CEO, Enable Injections)
§ Jesper Roested (CEO, Subcuject)
§ Pieter Muntendam (Former President and CEO, scPharmaceuticals)
§ Menachem Zucker (Vice President and Chief Scientist, Elcam Medical)
§ Graham Reynolds (Vice President and General Manager, Biologics, West Pharmaceutical Services)
§ Mindy Katz (Director of Product, SorrelMedical)
To request sample pages, please visit this - https://www.rootsanalysis.com/reports/238/request-sample.html
KeyQuestions Answered
§ Who are the leading developers of large volume wearable devices?
§ What are the prevalent trends within the large volume wearableinjectors market?
§ Which drug candidates are suited for delivery via large volumewearable injectors?
§ Who are the key contract service providers in this domain?
§ What are the various regulatory guidelines issued for medicaldevices across different regions?
§ How is the current and future market opportunity likely to bedistributed across key market segments?
You may also be interested in thefollowing titles:
- Microneedles and Needle-Free Injection Systems / Jet Injectors (Devices based on Spring, Gas and Other Mechanisms) Market, 2019-2030 [COVID-19 Series]
2. Global Autoinjectors Market (3rd Edition), 2020-2030
3. Prefilled SyringesMarket (5th Edition), 2020-2030
Contact Us:
Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091
Gaurav.Chaudhary@rootsanalysis.com
